keyword
MENU ▼
Read by QxMD icon Read
search

Acute lymphoblastic leukaemia

keyword
https://www.readbyqxmd.com/read/28211568/targeted-therapies-for-t-cell-acute-lymphoblastic-leukaemia-t-all-what-makes-t-all-tyk
#1
EDITORIAL
David J Curtis
No abstract text is available yet for this article.
February 17, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28208868/female-genital-tract-involvement-in-acute-lymphoblastic-leukemia-a-rare-case-report
#2
Vikram Narang, Amit Dhiman, Bhavna Garg, Neena Sood
Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma. Involvement of the uterus and cervix with Acute Lymphoblastic Leukaemia (ALL) is extremely rare, and ovarian involvement is even rarer. We report the case of a young lady who presented with tubo-ovarian mass, excessive post-operative bleeding (post-total abdominal hystrerctomy and bilateral salpingo-oophorectomy) and was diagnosed to have ALL with blood and tissue involvement by histopathology and flow cytometry...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28192788/metabolic-gatekeeper-function-of-b-lymphoid-transcription-factors
#3
Lai N Chan, Zhengshan Chen, Daniel Braas, Jae-Woong Lee, Gang Xiao, Huimin Geng, Kadriye Nehir Cosgun, Christian Hurtz, Seyedmehdi Shojaee, Valeria Cazzaniga, Hilde Schjerven, Thomas Ernst, Andreas Hochhaus, Steven M Kornblau, Marina Konopleva, Miles A Pufall, Giovanni Cazzaniga, Grace J Liu, Thomas A Milne, H Phillip Koeffler, Theodora S Ross, Isidro Sánchez-García, Arndt Borkhardt, Keith R Yamamoto, Ross A Dickins, Thomas G Graeber, Markus Müschen
B-lymphoid transcription factors, such as PAX5 and IKZF1, are critical for early B-cell development, yet lesions of the genes encoding these transcription factors occur in over 80% of cases of pre-B-cell acute lymphoblastic leukaemia (ALL). The importance of these lesions in ALL has, until now, remained unclear. Here, by combining studies using chromatin immunoprecipitation with sequencing and RNA sequencing, we identify a novel B-lymphoid program for transcriptional repression of glucose and energy supply...
February 13, 2017: Nature
https://www.readbyqxmd.com/read/28187480/-acute-lymphoblastic-leukaemia-in-adults
#4
Nicola Gökbuget
No abstract text is available yet for this article.
February 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28182813/second-malignant-neoplasms-in-childhood-cancer-survivors-treated-in-a-tertiary-paediatric-oncology-centre
#5
Jia Wei Lim, Frances Sh Yeap, Yiong Huak Chan, Allen Ej Yeoh, Thuan Chong Quah, Poh Lin Tan
Introduction: One of the most feared complications of childhood cancer treatment is second malignant neoplasms (SMNs). This study evaluates the incidence, risk factors and outcomes of SMNs in a tertiary paediatric oncology centre in Singapore. Materials and Methods: A retrospective review was conducted on patients diagnosed with childhood cancer under age 21 and treated at the National University Hospital, Singapore, from January 1990 to 15 April 2012. Case records of patients with SMNs were reviewed. Results: We identified 1124 cases of childhood cancers with a median follow-up of 3...
January 2017: Annals of the Academy of Medicine, Singapore
https://www.readbyqxmd.com/read/28179388/disseminated-intravascular-coagulation-like-reaction-following-rituximab-infusion
#6
Hind Rafei, Samah Nassereddine, Ivan F Garcia
Rituximab generally is a well-tolerated medication used in a variety of haematological and autoimmune conditions. The safety profile of the medication has been reviewed in the literature. Infusion reactions due to cytokine release are the most common side effects. With the increased use of rituximab, there is an increase incidence of cytopenias, most commonly thrombocytopenia and leucopenia. Coagulopathy is quite rare, reported previously in four cases in the literature. We highlighted the clinical course of a 39-year-old patient with precursor B-cell acute lymphoblastic leukaemia who was started on rituximab infusion...
February 8, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28139933/functionalised-triblock-copolymer-vectors-for-the-treatment-of-acute-lymphoblastic-leukaemia
#7
Robert C Deller, Paraskevi Diamanti, Gabriella Morrison, James Reilly, Benjamin Ede, Robert M Richardson, Kristian Le Vay, Andrew Michael Collins, Allison Blair, Adam W Perriman
The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute lymphoblastic leukaemia but like many other small molecule drugs, has low aqueous solubility. As a consequence, Parthenolide can only be administered clinically in the presence of harmful co-solvents. Accordingly, we describe the synthesis, characterisation and testing of a range of biocompatible triblock copolymer micelles as particle-based delivery vectors for the hydrophobic drug Parthenolide. The drug-loaded particles are produced via an emulsion-to-micelle transition method and the effects of introducing anionic and cationic surface charges on stability, drug sequestration, biocompatibility and efficacy are investigated...
January 31, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28139029/vincristine-induced-peripheral-neuropathy-in-survivors-of-childhood-acute-lymphoblastic-leukaemia
#8
Chee Geap Tay, Vanessa Wan Mun Lee, Lai Choo Ong, Khean Jin Goh, Hany Ariffin, Choong Yi Fong
BACKGROUND: Vincristine, an essential component of childhood acute lymphoblastic leukaemia (ALL) therapeutic protocols, is associated with dose-dependent neurotoxicity, but its long-term morbidity in treated children has not been clearly elucidated. The aim of this study is to determine the prevalence of vincristine-induced peripheral neuropathy (VIPN) among Malaysian childhood ALL survivors and its impact on motor function and quality of life. PROCEDURE: Survivors of childhood ALL aged 4-18 years who had completed chemotherapy for 2 years or more were evaluated for VIPN using both the clinical Total Neuropathy Score (cTNS) and nerve conduction studies...
January 31, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28116786/the-combination-of-bortezomib-with-chemotherapy-to-treat%C3%A2-relapsed-refractory-acute-lymphoblastic-leukaemia-of-childhood
#9
Alice Bertaina, Luciana Vinti, Luisa Strocchio, Stefania Gaspari, Roberta Caruso, Mattia Algeri, Valentina Coletti, Carmelo Gurnari, Mariateresa Romano, Maria Giuseppina Cefalo, Katia Girardi, Valentina Trevisan, Valentina Bertaina, Pietro Merli, Franco Locatelli
Achieving complete remission (CR) in childhood relapsed/refractory acute lymphoblastic leukaemia (ALL) is a difficult task. Bortezomib, a proteasome inhibitor, has in vitro activity against ALL blasts. A phase I-II trial, reported by the Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) consortium, demonstrated that bortezomib with chemotherapy has acceptable toxicity and remarkable activity in patients with relapsed ALL failing 2-3 previous regimens. We evaluated bortezomib in combination with chemotherapy in 30 and 7 children with B-cell precursor (BCP) and T-cell ALL, respectively...
January 24, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28069148/childhood-leukaemia-survivors-experiences-of-long-term-follow-ups-in-an-endocrine-clinic-a-focus-group-study
#10
Anna Pålsson, Marlene Malmström, Cecilia Follin
: The survival rate after childhood cancer has improved markedly and today more than 80% of patients will survive. Many childhood cancer survivors suffer from late complications due to radiotherapy and chemotherapy. Survivors of Acute Lymphoblastic Leukaemia (ALL), treated with cranial radiotherapy, are at a particularly high risk of having endocrine complications. PURPOSE: To illuminate childhood ALL survivors' experiences of a long-term follow-up in an endocrine clinic...
February 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28062297/the-association-between-mthfr-gene-c677t-polymorphism-and-all-risk-based-on-a-meta-analysis-involving-17-469-subjects
#11
Beibei Zhang, Weiming Zhang, Liang Yan, Daogang Wang
BACKGROUND: The methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism is closely related to the acute lymphoblastic leukaemia (ALL) indicated by many previous epidemiologic studies. However, their conclusions were still conflicting. METHODS: Our aim is to evaluate their associations using a more comprehensive updated meta-analysis. Electronic searches were conducted to select published studies prior to February, 2016. RESULTS: Totally, 39 case-control studies including 6551 ALL cases and 10,918 controls were selected in current meta-analysis...
January 3, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28039295/third-generation-cd28-4-1bb-chimeric-antigen-receptor-t-cells-for-chemotherapy-relapsed-or-refractory-acute-lymphoblastic-leukaemia-a-non-randomised-open-label-phase-i-trial-protocol
#12
Xiao-Yi Tang, Yao Sun, Ang Zhang, Guo-Liang Hu, Wei Cao, Dan-Hong Wang, Bin Zhang, Hu Chen
INTRODUCTION: There is no curative treatment available for patients with chemotherapy relapsed or refractory CD19+ B cells-derived acute lymphoblastic leukaemia (r/r B-ALL). Although CD19-targeting second-generation (2nd-G) chimeric antigen receptor (CAR)-modified T cells carrying CD28 or 4-1BB domains have demonstrated potency in patients with advanced B-ALL, these 2 signalling domains endow CAR-T cells with different and complementary functional properties. Preclinical results have shown that third-generation (3rd-G) CAR-T cells combining 4-1BB and CD28 signalling domains have superior activation and proliferation capacity compared with 2nd-G CAR-T cells carrying CD28 domain...
December 30, 2016: BMJ Open
https://www.readbyqxmd.com/read/28033648/characterisation-of-the-genomic-landscape-of-crlf2-rearranged-acute-lymphoblastic-leukemia
#13
Lisa J Russell, Lisa Jones, Amir Enshaei, Stefano Tonin, Sarra L Ryan, Jeyanthy Eswaran, Sirintra Nakjang, Elli Papaemmanuil, Jose M C Tubio, Adele K Fielding, Ajay Vora, Peter J Campbell, Anthony V Moorman, Christine J Harrison
Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic landscape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using multiple genomic approaches. Clinical and demographic features of CRLF2-r patients were characteristic of B-ALL. Patients with IGH-CRLF2 were older (14 y vs. 4 y, P < .001), while the incidence of CRLF2-r among Down syndrome patients was high (50/161, 31%)...
December 29, 2016: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/28032244/dasatinib-a-review-in-chronic-myeloid-leukaemia-and-ph-acute-lymphoblastic-leukaemia
#14
Gillian M Keating
Dasatinib (Sprycel(®)) is an orally administered, small molecule inhibitor of multiple tyrosine kinases. In the phase 3 DASISION trial, dasatinib 100 mg once daily resulted in deeper and faster cytogenetic and molecular responses than imatinib 400 mg once daily in patients with newly diagnosed, chronic-phase chronic myeloid leukaemia (CML), although there was no significant between-group difference in progression-free survival (PFS) or overall survival (OS) in the longer term. In the phase 3 CA180-034 trial, a regimen of dasatinib 100 mg once daily provided the most favourable benefit-risk profile in patients with imatinib-resistant or -intolerant chronic-phase CML...
January 2017: Drugs
https://www.readbyqxmd.com/read/28018703/successful-stem-cell-transplantation-in-a-patient-with-pretransplant-hepatic-inflammatory-pseudotumour
#15
Sanjay de Mel, Zarni Soe, Benjamin Wong, Ching Ching Ong, Lynette Teo, Lip Kun Tan
Inflammatory pseudotumours (IPT) are rare benign neoplasms of unknown aetiology. We present a case of hepatic IPT which was incidentally discovered in a patient with relapsed B-acute lymphoblastic leukaemia (B-ALL) undergoing pretransplant workup. After investigation to exclude an infective cause she underwent a reduced intensity conditioning stem cell transplant (SCT) successfully and currently remains well and in remission. On repeat liver MRI after SCT, the IPT was seen to be resolving. To the best of our knowledge this is the first report of an adult patient with hepatic IPT successfully undergoing SCT...
2016: Case Reports in Transplantation
https://www.readbyqxmd.com/read/27989379/epidemiology-of-invasive-aspergillosis-and-azole-resistance-in-patients-with-acute-leukaemia-the-sepia-study
#16
Philipp Koehler, Axel Hamprecht, Oliver Bader, Isabelle Bekeredjian-Ding, Dieter Buchheidt, Gottfried Doelken, Johannes Elias, Gerhard Haase, Corinna Hahn-Ast, Meinolf Karthaus, Alexander Kekulé, Peter Keller, Michael Kiehl, Stefan W Krause, Carolin Krämer, Silke Neumann, Holger Rohde, Paul La Rosée, Markus Ruhnke, Philippe Schafhausen, Enrico Schalk, Katrin Schulz, Stefan Schwartz, Gerda Silling, Peter Staib, Andrew Ullmann, Maria Vergoulidou, Thomas Weber, Oliver A Cornely, Maria J G T Vehreschild
Invasive aspergillosis (IA) is a serious hazard to high-risk haematological patients. There are increasing reports of azole-resistant Aspergillus spp. This study assessed the epidemiology of IA and azole-resistant Aspergillus spp. in patients with acute leukaemia in Germany. A prospective multicentre cohort study was performed in German haematology/oncology centres. The incidence of probable and proven aspergillosis according to the revised EORTC/MSG criteria was assessed for all patients with acute leukaemia [acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL)]...
December 12, 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27986446/-peripheral-magnetic-resonance-scan-in-the-diagnosis-of-acute-lymphoblastic-leukaemia
#17
María Dolores Ruiz Montesino, Virginia Moreira Navarrete, Carmen Vargas Lebrón
No abstract text is available yet for this article.
December 13, 2016: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/27984637/genomic-characterization-of-paediatric-acute-lymphoblastic-leukaemia-an-opportunity-for-precision-medicine-therapeutics
#18
REVIEW
Sarah K Tasian, Stephen P Hunger
Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (ALL) have enhanced the understanding of key biological subsets of de novo and relapsed ALL, which has led to improved risk stratification of patients. These achievements have further defined critical leukaemia-associated pathways and somatic alterations that may be preferentially sensitive to treatment with kinase inhibitors, epigenetic therapy or other novel agents. Therapeutic success in childhood ALL currently relies upon refined risk stratification of patients based on (i) underlying biological and clinical characteristics, and (ii) depth of initial treatment response with appropriate modulation of chemotherapy intensity...
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27979926/crebbp-knockdown-enhances-ras-raf-mek-erk-signalling-in-ras-pathway-mutated-acute-lymphoblastic-leukaemia-but-does-not-modulate-chemotherapeutic-response
#19
Zach A Dixon, Lindsay Nicholson, Martin Zeppetzauer, Elizabeth Matheson, Paul Sinclair, Christine J Harrison, Julie A E Irving
Relapsed acute lymphoblastic leukaemia is the most common cause of cancer related mortality in young people and new therapeutic strategies are needed to improve outcome. Recent studies have shown that heterozygous inactivating mutations in the histone acetyl transferase, CREBBP, are particularly frequent in relapsed childhood acute lymphoblastic leukaemia and associated with a hyperdiploid karyotype and KRAS mutations. To study the functional impact of CREBBP haploinsufficiency in acute lymphoblastic leukaemia, RNA interference was used to knock down expression of CREBBP in acute lymphoblastic leukaemia cell lines and various primagraft acute lymphoblastic leukaemia cells...
December 15, 2016: Haematologica
https://www.readbyqxmd.com/read/27977050/the-promise-of-chimeric-antigen-receptor-t-cells-carts-in-leukaemia
#20
REVIEW
Robert J Orlowski, David L Porter, Noelle V Frey
The success of genetically engineered T cells that express chimeric antigen receptors (CARTs) has been a momentous step forward in harnessing the potent cancer fighting abilities of the immune system. The efficacy seen in relapsed/refractory (r/r) acute lymphoblastic leukaemia (ALL), not only by inducing remission, but also in maintaining long-term disease control, has been unprecedented. While the foundation for this approach has been firmly set in place, continued development will improve the efficacy, toxicity and applicability to other malignancies of this new class of 'living drugs'...
December 15, 2016: British Journal of Haematology
keyword
keyword
25317
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"